To investigate the activity of NKAR-expressing NK-92 cells in combination with bispecific NKAB molecules in such a setting, we established an in vitro model based on murine GL261 glioblastoma cells lentivirally transduced to express one or both of the human EGFR and ErbB2 target antigens on their surface, allowing for the specific binding of the bispecific killer cell engagers (Supplementary Figure S5). The gene discussed is EGFR; the disease is glioblastoma.